Drugs / MK-4721
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00519233 | Sep 2007 → Sep 2009 | prostate cancer | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01608711 | Aug 2012 → Nov 2015 | pancreatic ductal adenocarcinoma | Agensys, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00902291 | Apr 2009 → Apr 2012 | pancreatic ductal adenocarcinoma | Astellas Pharma Inc | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-4721 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109548 ↗ |
| Known as | AGS-1C4D4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00519233 ↗ |
| Known as | AGS-PSCA | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109548 ↗ |
| Action | Inhibit | “Prostate stem cell antigen inhibitor” CHEMBL2109548 ↗ |
| Route | Intravenous | “IV infusion” NCT00902291 ↗ |
| Target | PSCA | “Prostate stem cell antigen inhibitor” CHEMBL2109548 ↗ |